Pfizer Finalizes $2.3B Bextra Off-Label Marketing Deal

By Evan Weinberger · September 2, 2009, 5:13 PM EDT

Pfizer Inc. will pay $2.3 billion and one of its subsidiaries will plead guilty to a criminal charge to settle claims that the drug giant improperly marketed the discontinued anti-inflammatory drug...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Evan

January 04, 2018
Sessions' Reversal Likely To Kill Any Pot Buzz For Banks
March 02, 2017
Lawmakers Urge AG To Keep Federal Pot Policy In Place
February 13, 2017
Sessions Could Further Blunt Bank Access For Pot Biz
February 08, 2017
Groups Sue To Block Trump's 2-For-1 Regulatory Order
February 01, 2017
Senate Panel Advances Price, Mnuchin Without Dems Present
November 09, 2016
Trump's Upset Win Puts Obama Legacy On Chopping Block
July 10, 2015
Senate Bill Would Ease Bank Access For Legal Pot Shops
April 10, 2015
GE To Provide Road Map For Firms To Escape SIFI-Dom
December 11, 2014
CFPB Tells Credit Bureaus To Name Bad Debt Reporters
January 08, 2014
Senators Seek More Clarity On Fed. Agency Settlements